Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL I.V. RTU IN PLASTIC CONTAINER vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Treatment of anaerobic bacterial infections (intra-abdominal, skin and skin structure, gynecologic, bone and joint, central nervous system, lower respiratory tract, endocarditis),Treatment of trichomoniasis (symptomatic and asymptomatic),Treatment of bacterial vaginosis,Treatment of amebiasis (intestinal and hepatic),Prophylaxis of postoperative infection in contaminated or potentially contaminated colorectal surgery,Off-label: Management of Clostridium difficile infection, Helicobacter pylori eradication (part of combination therapy), Crohn's disease (perianal fistulas), rosacea (topical)
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy-metronidazole (active) and acid metabolites. Enzymes: CYP450 (primarily CYP2A6 and CYP3A4).
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
<20%, primarily to albumin.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.8-1.2 L/kg; indicates extensive tissue penetration including CNS, bone, and abscesses.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Oral: 100% (nearly complete absorption).
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
No adjustment required for GFR >10 m L/min. For GFR <10 m L/min: administer every 12 hours. Hemodialysis: administer normal dose after dialysis; no supplemental dose needed. Peritoneal dialysis: administer normal dose every 12 hours.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 7.5 mg/kg every 12 hours). Child-Pugh C: use contraindicated or reduce dose to 7.5 mg/kg every 24 hours with close monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Neonates (0-6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 12 hours. Infants/children (>6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
No specific dose adjustment based solely on age. Monitor renal function and adjust if GFR <10 m L/min. Consider reduced hepatic clearance; use lowest effective dose and monitor for adverse effects.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Its use should be reserved for conditions described in the indications. Unnecessary use should be avoided.
There is no FDA black box warning for ALPHACAINE.
Carcinogenicity risk (animal data; avoid unnecessary use),Seizures and peripheral neuropathy (discontinue if abnormal neurologic signs occur),Hepatic impairment: dose adjustment may be required; caution in severe liver disease,Renal impairment: accumulation of metabolites; monitor for toxicity,Blood dyscrasias: history of or current; monitor CBC with prolonged therapy,Candidiasis: may cause overgrowth; treat appropriately,Disulfiram-like reaction with alcohol: avoid alcohol during and for 48 hours after therapy,Drug interactions: warfarin (increased INR), lithium (increased toxicity), CYP450 inducers/inhibitors,Pregnancy: reserve for serious infections; use in trichomoniasis only if no alternative,Lactation: discontinue breastfeeding or drug, considering importance to mother
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Hypersensitivity to metronidazole or other nitroimidazoles,First trimester of pregnancy (for trichomoniasis; relative contraindication),Concurrent use of disulfiram (psychotic reactions possible),Patients with Cockayne syndrome (risk of severe hepatic adverse reactions)
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
No direct food interactions, but alcohol and alcohol-containing foods (e.g., sauces, vinegar, fermented products) must be strictly avoided during therapy and for 48 hours after completion due to risk of disulfiram-like reaction.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: Generally considered safe for short-term treatment of bacterial vaginosis or trichomoniasis; no evidence of increased major malformations. However, use only if clearly needed.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Infant serum levels may be up to 20% of maternal levels. Due to potential carcinogenicity in animal studies and concerns for infant gastrointestinal effects, the manufacturer recommends discontinuing breastfeeding during therapy and for 24-48 hours after last dose. Alternative washing and pumping may be considered.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
Pregnancy may alter metronidazole pharmacokinetics: slightly increased clearance and volume of distribution. No specific dose adjustment is recommended; use standard dosing (e.g., 500 mg IV every 6-8 hours for anaerobic infections). Avoid high doses and prolonged therapy unless essential.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
Flagyl IV RTU (metronidazole) is a nitroimidazole antibiotic used for anaerobic infections and protozoal diseases. Avoid alcohol during therapy and for 48 hours after due to disulfiram-like reaction. Infuse slowly over 30-60 minutes to minimize infusion reactions. Monitor for peripheral neuropathy and CNS effects with prolonged use. Use with caution in hepatic impairment; adjust dose in severe liver disease. May cause metallic taste. Do not mix with other drugs in the same IV line. Contraindicated in first trimester of pregnancy unless life-threatening.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Do not drink alcohol or use products containing alcohol during treatment and for at least 48 hours after the last dose; this can cause severe nausea, vomiting, flushing, and headache.,This medication may cause a metallic taste in the mouth, which is temporary.,If you experience numbness, tingling, or pain in your hands or feet, or any signs of an allergic reaction, contact your healthcare provider immediately.,For IV administration, the infusion site should be monitored for signs of redness, swelling, or pain.,Take the medication exactly as prescribed; do not stop without consulting your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL I.V. RTU IN PLASTIC CONTAINER vs ALPHACAINE, answered by our medical review team.
FLAGYL I.V. RTU IN PLASTIC CONTAINER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL I.V. RTU IN PLASTIC CONTAINER and ALPHACAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL I.V. RTU IN PLASTIC CONTAINER is: Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL I.V. RTU IN PLASTIC CONTAINER and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL I.V. RTU IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: General. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.